Home Newsfeeds Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Barclays analyst Peter Lawson maintains Immunogen (NASDAQ:IMGN) with a Overweight and raises the price target from $8 to $9.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Barclays analyst Peter Lawson maintains Immunogen (NASDAQ:IMGN) with a Overweight and raises the price target from $8 to $9.

Stephens & Co. Maintains Equal-Weight on Yellow, Lowers Price Target to $5

By Benzinga Newsdesk

November 7, 11:32 AM

Stephens & Co. analyst Jack Atkins maintains Yellow (NASDAQ:YELL) with a Equal-Weight and lowers the price target from $7 to $5.

YELL

NetApp Q1 Adj. EPS $1.20 Beats $1.10 Estimate, Sales $1.59B Beat $1.55B Estimate

By Michael Horton

August 24, 4:02 PM

NetApp (NASDAQ:NTAP) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $1.10 by 9.09 percent. This is a 4.35 percent increase over earnings of $1.15 per share from the same

NTAP

News

Why Under Armour Shares Are Rising

By Henry Khederian

September 29, 12:07 PM

Under Armour Inc (NYSE: UA) (NYSE: UAA) shares are trading higher by roughly 4.6% to $6.38 Friday morning. Shares of retail and athletic apparel stocks are trading higher.

NKE

Piper Sandler Initiates Coverage On Inter Parfums with Overweight Rating, Announces Price Target of $102

By Benzinga Newsdesk

September 9, 5:02 AM

Piper Sandler analyst Korinne Wolfmeyer initiates coverage on Inter Parfums (NASDAQ:IPAR) with a Overweight rating and announces Price Target of $102.

IPAR

Barclays Maintains Overweight on Immunogen, Raises Price Target to $9

Related Posts

Stephens & Co. Maintains Equal-Weight on Yellow, Lowers Price Target to $5

NetApp Q1 Adj. EPS $1.20 Beats $1.10 Estimate, Sales $1.59B Beat $1.55B Estimate

Why Under Armour Shares Are Rising

Piper Sandler Initiates Coverage On Inter Parfums with Overweight Rating, Announces Price Target of $102